Caladrius Biosciences Announces Participation in Upcoming Conferences in October 2021
October 04 2021 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of cellular therapies designed to
reverse disease, today announced its participation in several
industry and investor events:
- UK Kidney Week® Virtual Conference (October 4-7,
2021)Location: VirtualSession
Title: Discovering Effective New Targets for Therapy in
Kidney DiseaseSession Date/Time: Monday, October
4th at 5:00pm – 6:30pm BST / 12:00pm – 1:30pm
EDTPresenter: David J. Mazzo, PhD, President and
CEOArranged by the UK Kidney Association, the UK Kidney Week®
annual conference is the biggest multi-disciplinary UK event for
the renal community to showcase the best in-clinical and
basic-science research, as well as quality improvement work. For
more information on the conference and how to register, please
visit https://ukkw.org.uk/.
- Advanced Therapies Congress & Expo (October 5-6,
2021)Location: ExCeL, London,
UKSession Title: Caladrius Biosciences; Progress,
challenges and learnings during the COVID-19
pandemicPresentation Date/Time: Tuesday, October
5th at 5:30pm BST / 12:30pm EDTPresenter: David J.
Mazzo, PhD, President and CEOThe Advanced Therapies Congress &
Expo will look at what’s happened in the industry in the last year,
what the effect of the COVID-19 outbreak has been, good and bad,
and how we evolve from here. For more information on the conference
and how to register, please visit
https://www.terrapinn.com/congress/advanced-therapies/index.stm.
- The LD Micro Main Event (October 12-14,
2021)Location: Luxe Sunset Bel Air (Los
Angeles)Presentation Date/Time: Wednesday, October
13th at 9:30am PDT / 12:30pm EDTPresenter: David
J. Mazzo, PhD, President and CEOThe 2021 LD Micro Main Event will
be held at the Luxe Sunset Bel-Air in Los Angeles from Tuesday,
October 12th to Thursday, October 14th. This three-day, investor
conference is expected to feature around 150 companies, presenting
for 25 minutes each, as well as several influential keynotes in
person. For more information on the conference and how to register,
please contact Dean@ldmicro.com.
- Dawson James Securities Small Cap Growth Conference
(October 20-21, 2021)Location: Wyndham
Grand Hotel, Jupiter FLPresentation Date/Time:
Thursday, October 21st at 10:10am EDTPresenter:
David J. Mazzo, PhD, President and CEODawson James’ flagship Small
Cap Growth Conference will bring together senior executives from
approximately 40 small-cap growth companies operating at the
forefront of the healthcare, technology and consumer sectors. The
conference brings together institutional funds, family offices and
high-net-worth accredited investors. For more information on the
conference and how to register, please visit
https://dawsonjames.com/.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: XOWNA®
(formerly CLBS16), the subject of both a recently completed
positive Phase 2a study and a newly initiated Phase 2b study
(www.freedom-trial.com) in the U.S. for the treatment of coronary
microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan),
recipient of orphan designation for Buerger’s Disease in the
U.S. and, in Japan, recipient of a SAKIGAKE designation and
eligible for early conditional approval for the treatment of
critical limb ischemia (“CLI”) and Buerger’s Disease based on the
results of an ongoing clinical trial; and CLBS201, designed to
assess the safety and efficacy of CD34+ cell therapy as a treatment
for diabetic kidney disease (“DKD”). For more information on
the Company, please visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email:
jmenditto@caladrius.com
Media: Real ChemistryRachel GirardReal ChemistryPhone:
401-477-4030Email: rgirard@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024